20Sプロテアソーム治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:20s Proteasome - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0500
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:77
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥367,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥735,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,102,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

20s Proteasome – Pipeline Review, H2 2019
Summary

20s Proteasome – 20S proteasome is the catalytic core of the 26S proteasome, the central protease of the ubiquitin pathway of protein degradation. It is commonly associated with regulatory complexes, which include the 19S Proteasome, the PA28 alpha/beta complex, or the PA28 gamma complex. The 20S Proteasome is composed of 28 subunits arranged into four stacked rings. Unlike the 26S proteasome, which degrades proteins in an ATP-dependent manner, the 20S proteasome is ATP-independent and only degrades entirely unfolded polypeptides.

20s Proteasome pipeline Target constitutes close to 9 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 1 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease and Metabolic Disorders which include indications Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Multiple Myeloma (Kahler Disease), Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Amyloidosis, Colon Cancer, Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme (GBM), Gliosarcoma, Graft Versus Host Disease (GVHD), Kidney Transplant Rejection, Leukemia, Lung Transplant Rejection, Malignant Glioma, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Renal Cell Carcinoma, Neuroendocrine Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Peripheral T-Cell Lymphomas (PTCL), Renal Cell Carcinoma, Small-Cell Lung Cancer and Tuberculosis.

The latest report 20s Proteasome – Pipeline Review, H2 2019, outlays comprehensive information on the 20s Proteasome targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in 20s Proteasome targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for 20s Proteasome
- The report reviews 20s Proteasome targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in 20s Proteasome targeted therapeutics and enlists all their major and minor projects
- The report assesses 20s Proteasome targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to 20s Proteasome targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for 20s Proteasome
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding 20s Proteasome development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
20s Proteasome – Overview
20s Proteasome – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
20s Proteasome – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
20s Proteasome – Companies Involved in Therapeutics Development
Amgen Inc
Bristol-Myers Squibb Co
Centrax International Inc
Hibiskus Biopharma Inc
HuniLife Biotechnology Inc
20s Proteasome – Drug Profiles
carfilzomib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CX-13608 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HuL-002 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
marizomib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oprozomib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RTSV-5 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit 20S Proteasome for Oncology – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit 20s Proteasome for Tuberculosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TIR-199 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
20s Proteasome – Dormant Products
20s Proteasome – Product Development Milestones
Featured News & Press Releases
Dec 11, 2019: Amgen reports positive data in multiple myeloma study
Dec 02, 2019: Amgen announces data to be presented on KYPROLIS (carfilzomib) at ASH 2019
Sep 13, 2019: Amgen announces phase 3 CANDOR study combining KYPROLIS (carfilzomib) and DARZALEX (daratumumab) meets primary endpoint of progression-free survival
Sep 12, 2019: Amgen highlights new data From KYPROLIS (carfilzomib) and Oncology Pipeline At IMW 2019
Aug 19, 2019: Carfilzomib (Kyprolis): reminder of risk of potentially fatal cardiac events
Jun 19, 2019: Early Indications of potential Heart Conditions Using Carfilzomib in Multiple Myeloma
Jun 13, 2019: Cardiac toxicity risk factors identified with relapsed multiple myeloma therapy
Apr 25, 2019: Amgen agree to pay a total of nearly $24.75 million to resolve allegations that it paid kickbacks through copay assistance foundations
Mar 19, 2019: ONO submits supplemental application of Kyprolis for intravenous injection, a proteasome inhibitor, for additional dosage and administration for the treatment of relapsed or refractory multiple myeloma in Japan
Nov 01, 2018: Amgen to present new data on Carfilzomib at ASH 2018
Oct 01, 2018: FDA approves KYPROLIS (carfilzomib) once-weekly 70 mg/m2 in combination With Dexamethasone (Kd70) for patients with Relapsed Or Refractory Multiple Myeloma
Aug 27, 2018: Amgen Submits Supplemental New Drug Application For KYPROLIS (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone
Jun 11, 2018: FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS (carfilzomib) Label
Jun 01, 2018: Phase 3 A.R.R.O.W. Interim Analysis Shows Once-Weekly 70 mg/m2 KYPROLIS (carfilzomib) Regimen Significantly Extended Progression-Free Survival Versus A Twice-Weekly 27 mg/m2 Regimen In Patients With Relapsed And Refractory Multiple Myeloma
May 09, 2018: UAB recruiting for clinical trial to determine therapies for eradication of multiple myeloma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Amgen Inc, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Centrax International Inc, H2 2019
Pipeline by Hibiskus Biopharma Inc, H2 2019
Pipeline by HuniLife Biotechnology Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019

【掲載企業】

Amgen Inc
Bristol-Myers Squibb Co
Centrax International Inc
Hibiskus Biopharma Inc
HuniLife Biotechnology Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[20Sプロテアソーム治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆